At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 37 target
Drug / intervention
Albumin Bound Paclitaxel +1 moredrug
Likely dose
Albumin Bound Paclitaxel 150 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer
In Brief
A Phase 2 clinical trial evaluating Albumin Bound Paclitaxel and 5-FU for Gastric Caner. Targeting 37 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effectiveness and safety of albumin bound paclitaxel plus 5-FU and as second-line therapy in the treatment of taxanes naive patients with advanced gastric cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Caner
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedAug 2014
Primary CompletionDec 2014
TodayJul 2026
First PostedAug 29, 2014
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2014
TodayJul 1, 2026
Enrollment to primary: 4.1 yearsPosted 11.8 years ago
Interventions
Albumin Bound Paclitaxeldrug
Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
5-FUdrug
5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.